Bayer Aktiengesellschaft (BAYZF)
| Market Cap | 53.62B +151.8% |
| Revenue (ttm) | 53.81B -1.9% |
| Net Income | -232.31M |
| EPS | -0.24 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 9.21 |
| Dividend | 0.13 (0.23%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 207 |
| Average Volume | 14,477 |
| Open | 54.70 |
| Previous Close | 54.67 |
| Day's Range | 54.70 - 54.70 |
| 52-Week Range | 20.99 - 55.11 |
| Beta | 0.97 |
| RSI | 71.54 |
| Earnings Date | Feb 25, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial numbers in EUR Financial StatementsNews
Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month
WHIPPANY, N.J.--(BUSINESS WIRE)--This American Heart Month, Bayer® Aspirin continues its mission to help people uncover the heart health risk factors they may not see with the launch of the Heart to H...
Oakmark International Strategy Q4 2025 Contributors And Detractors
Oakmark International Strategy portfolio's return was 4.93% (net) for the reporting period vs. MSCI World ex USA Index that returned 5.20% for the same period.
Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention Transcript
Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention February 6, 2026 9:00 AM...
DAX Rises After Flat Start; Rheinmetall, Bayer Among Top Gainers
(RTTNews) - After a flat start, Germany stock market's key index DAX moved up smartly on Friday, with stocks from several sectors gaining in strength on sustained buying interest. Concerns about AI-re...
Bayer's (BAYRY) Asundexian Significantly Reduces Stroke Risk in Phase 3 Trial
Bayer's (BAYRY) Asundexian Significantly Reduces Stroke Risk in Phase 3 Trial
Bayer stroke prevention drug asundexian shows positive results in phase 3 trial
Bayer says its experimental blood thinner cuts risk of stroke recurrence by 26%
Bayer said on Thursday its experimental blood thinner cut the risk of stroke recurrence by 26% in a late-stage trial, in a fresh boost for CEO Bill Anderson's turnaround efforts.
Bayer's Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo
NEW ORLEANS--(BUSINESS WIRE)--Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibito...
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL' Campaign
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL' Campaign.
Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar
Bayer to build new canola research and development site in Winnipeg
Bayer says it will put more than $45 million toward building a new research and development facility in Winnipeg.
Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada
CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada's leadership in canola innovation by establishing a cutting-edge...
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
BERLIN--(BUSINESS WIRE)--Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two...
Bayer Announces FDA's Orphan Drug Designation For OpCT-001 To Treat Retinitis Pigmentosa
(RTTNews) - Bayer AG (BYR.L, BAY.MI, BAYN.DE) and its independently operated subsidiary BlueRock Therapeutics LP announced that its investigational cell therapy, OpCT-001, has received Orphan Drug Des...
Bayer Shares Jump as Supreme Court Agrees to Review Key Roundup Case
BAYRY jumps 6.4% after the Supreme Court agrees to review the Durnell Roundup case, a key test of federal preemption in glyphosate litigation.
Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases
BERLIN & NASHVILLE, Tenn.--(BUSINESS WIRE)--Bayer and Vanderbilt University Medical Center (VUMC) today announced that they have entered a strategic five-year collaboration agreement to advance innova...
Bayer: Timing Upside In 2025, More Upside Possible But Risky In 2026E (Downgrade)
Bayer Shares Rise After U.S Supreme Court Agrees to Review Roundup Case
Bayer : U.S. Supreme Court To Review Durnell Case In Roundup Litigation
(RTTNews) - Bayer announced that the U.S. Supreme Court has agreed to review the Durnell case in the ongoing Roundup litigation. The Court's decision follows a petition filed by Monsanto in April 2025...
Supreme Court to hear Bayer's appeal to block thousands of Roundup weedkiller lawsuits
Bayer is arguing that consumers should not be able to sue it under state law for failing to warn that Roundup increases cancer risk because the Environmental Protection Agency has found no such risk a...
Bayer (BAYZF) Sees 5% Gain as U.S. Supreme Court Agrees to Hear Roundup Appeal
Bayer (BAYZF) Sees 5% Gain as U.S. Supreme Court Agrees to Hear Roundup Appeal
Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation
LEVERKUSEN--(BUSINESS WIRE)--The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in ...
Supreme Court takes up Bayer’s bid to limit Roundup weedkiller liability
The Supreme Court on Friday took up a bid from Bayer to limit liability for pesticide makers, including Bayer’s Roundup weedkiller, which has become the subject of numerous cancer suits. The court sai...
Bayer gains after U.S. Supreme Court grants hearing on Roundup suits
Bayer (BAYZF) shares jump after Supreme Court agrees to hear Roundup appeal, impacting 67,000 lawsuits.